Non-Small Cell Lung Cancer (NSCLC) is the most common form of lung cancer. Most patients with NSCLC harbor epidermal growth factor receptor (EGFR) mutations like T790M/L858R (EGFRTL), L858R (EGFRLR), and exon 19 deletion (EGFRD19). While Osimertinib (Osi) is the standard treatment for patients with EGFR mutations, resistance to the drug inevitably develops, leading to therapeutic failure. The role of the tumor microenvironment (TME) in driving resistance remains underexplored, limiting the development of more effective therapies. Therefore, we employ in vitro models and genetically engineered mouse models (GEMMs) to investigate potential bypass mechanisms of Osi resistance using RNA sequencing (RNAseq), single-cell RNA sequencing (scRNAseq) and high-resolution transcriptomics.
P3.03.15 Investigating Mechanisms of Resistance in EGFR-Mutated Non-Small Cell Lung Cancer Through High Resolution Transcriptomics
Eva Cabrera San MillanPrimo
;R. Mercatelli;P. Armanetti;E. Bramanti;G. Maroni;E. Levantini
2025-01-01
Abstract
Non-Small Cell Lung Cancer (NSCLC) is the most common form of lung cancer. Most patients with NSCLC harbor epidermal growth factor receptor (EGFR) mutations like T790M/L858R (EGFRTL), L858R (EGFRLR), and exon 19 deletion (EGFRD19). While Osimertinib (Osi) is the standard treatment for patients with EGFR mutations, resistance to the drug inevitably develops, leading to therapeutic failure. The role of the tumor microenvironment (TME) in driving resistance remains underexplored, limiting the development of more effective therapies. Therefore, we employ in vitro models and genetically engineered mouse models (GEMMs) to investigate potential bypass mechanisms of Osi resistance using RNA sequencing (RNAseq), single-cell RNA sequencing (scRNAseq) and high-resolution transcriptomics.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
